The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have EGFR Mutant non-small cell lung cancer. The purpose of this study is to test if the combination of CB-839 HCl (telaglenastat) and AZD9291 is safe in patients with non-small cell lung cancer.
If you join this study you will receive CB-839 HCl (telaglenastat) and AZD9291. The total treatment duration is unknown as you will receive the study drugs as long as your disease status does not worsen or no other reasons for stopping occur.
Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.
Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT03831932